$QURE

Balachandran Madhavan sold $526K of QURE

Balachandran Madhavan sold 11,685 shares of uniQure N.V. (QURE) at an average of $45.06 ($42.60–$47.08, $0.53M total) across 3 trades on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Balachandran Madhavan
Published Jun 22, 2026, 12:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 12:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QURE
Neutral
medium confidence
Mentioned
$QURE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

The disclosed open-market sale totals $526,484.60 across three trades on 2026-06-17, with a stated 10b5-1 pre-arranged plan.

02

Market read

This provides a fresh datapoint on insider activity, but it does not introduce new fundamentals or catalysts for QURE.

03

What to watch

Traders may over-weight insider sales; without concurrent news (trial results, guidance, financing), the signal is usually weak and should be treated as sentiment noise.

Relevance 4/10Novelty 4/10Timing: after-hours/next-session read-through from a newly filed Form 4 (filed 2026-06-22)

Background

The article is a newly filed SEC Form 4 insider transaction for uniQure N.V. (QURE) by director Balachandran Madhavan.

Company-level read

Ticker impact

$QURENeutralMedium confidence
Context

uniQure director Balachandran Madhavan sold $526,484 of QURE shares via an open-market sale under a 10b5-1 plan on 2026-06-17.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional fundamental implication from this Form 4 alone.

Evidence & confidence

The filing is a routine Form 4 insider transaction with disclosed trade size, dates, and 10b5-1 pre-arrangement, without any accompanying operational or guidance change.

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory/clinical catalyst mentioned.

None indicated; no cross-border deal, listing, or macro linkage described.

None indicated; no global partnership, trial, or financing event disclosed.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity/tax planning rather than bearish expectations.

Key entities

  • uniQure N.V.

    Subject of the Form 4 insider transaction; director Balachandran Madhavan sold shares.

  • Balachandran Madhavan

    Director who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

Med

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.